AC
CORT icon

Allstate Corporation’s Corcept Therapeutics CORT Stock Holding History

Allstate Corporation’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
+2,896
New +$175K ﹤0.01% 1251

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Corporation's CORT Position: Q2 2026 in Review

Allstate Corporation opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,896 shares worth $252K. The stake represents ﹤0.01% of the portfolio and ranks #1251 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Allstate Corporation held 2,896 shares of Corcept Therapeutics worth $252K as of Q2 2026.
  • Corcept Therapeutics was a new Allstate Corporation position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1251 holding.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.